SCHEMBL2894409

SCHEMBL2894409

CN1CCN(c2ccc(N)c(N)c2F)CC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.60
L3MBTL1 Q9Y468 1/20 0.60
ADRA2C P18825 3/20 0.53
KDM4E B2RXH2 4/20 0.53
MAPT P10636 3/20 0.53
GAA P10253 3/20 0.53
PTK2B Q14289 2/20 0.53
HTT P42858 2/20 0.53
MAPK1 P28482 1/20 0.53
RECQL P46063 1/20 0.53
POLB P06746 1/20 0.51
RAD52 P43351 1/20 0.47
HSD17B10 Q99714 1/20 0.46
GFER P55789 1/20 0.43
KMT2A Q03164 1/20 0.43
ESR2 Q92731 1/20 0.43
HRH4 Q9H3N8 3/20 0.40
NCF1 P14598 1/20 0.39
DRD2 P14416 3/20 0.39
DRD3 P35462 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16514423 0.87 ALDH1A1 (0.62) ALDH1A1L3MBTL1ADRA2CKDM4EMAPT
SCHEMBL22471212 0.84 ALDH1A1 (0.58) ALDH1A1L3MBTL1ADRA2CKDM4EMAPT
SCHEMBL30464713 0.84 ALDH1A1 (0.58) ALDH1A1L3MBTL1ADRA2CKDM4EMAPT
SCHEMBL940595 0.83 ALDH1A1 (0.53) ALDH1A1L3MBTL1KDM4EMAPTGAA
SCHEMBL24620621 0.83 ALDH1A1 (0.57) ALDH1A1L3MBTL1ADRA2CKDM4EMAPT
SCHEMBL21031350 0.81 ALDH1A1 (0.56) ALDH1A1L3MBTL1KDM4EMAPTGAA
SCHEMBL22471227 0.81 ALDH1A1 (0.58) ALDH1A1L3MBTL1ADRA2CKDM4EMAPT
SCHEMBL22164011 0.80 ALDH1A1 (0.54) ALDH1A1L3MBTL1ADRA2CKDM4EMAPT
SCHEMBL10061518 0.80 ALDH1A1 (0.54) ALDH1A1L3MBTL1ADRA2CKDM4EMAPT
SCHEMBL28425579 0.80 ALDH1A1 (0.54) ALDH1A1L3MBTL1ADRA2CKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3740478-B1 FUSED IMIDAZOLE DERIVATIVES AS IL-17 MODULATORS UCB Biopharma SRL (BE) 2023-11-01 EP disclosed
CN-111601799-B Fused imidazole derivatives as Il-17 modulators UCB生物制药有限责任公司 2023-06-09 CN disclosed
US-11472794-B2 Fused imidazole derivatives as IL-17 modulators UCB Biopharma SRL (BE) 2022-10-18 US disclosed
US-20210053952-A1 Fused Imidazole Derivatives as IL-17 Modulators UCB Biopharma SRL (BE) 2021-02-25 US disclosed
EP-3740478-A1 FUSED IMIDAZOLE DERIVATIVES AS IL-17 MODULATORS UCB Biopharma SRL (BE) 2020-11-25 EP disclosed
CN-111601799-A Fused imidazole derivatives as Il-17 modulators UCB生物制药有限责任公司 2020-08-28 CN disclosed
US-8614330-B2 Substituted benz-azoles and methods of their use as inhibitors of RAF kinase NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2013-12-24 US disclosed
US-20120288501-A1 SUBSTITUTED BENZAZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE NOVARTIS VACCINES AND DIAGNOSTICS, INC. FORMERLY KNOWN AS CHIRON CORPORATION (US) 2012-11-15 US disclosed
US-20120288501-A1 SUBSTITUTED BENZAZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE NOVARTIS VACCINES AND DIAGNOSTICS, INC. FORMERLY KNOWN AS CHIRON CORPORATION (US) 2012-11-15 US disclosed
US-20120288501-A1 SUBSTITUTED BENZAZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE NOVARTIS VACCINES AND DIAGNOSTICS, INC. FORMERLY KNOWN AS CHIRON CORPORATION (US) 2012-11-15 US disclosed
US-20070299039-A1 Substituted benz-azoles and methods of their use as inhibitors of Raf kinase CHIRON CORPORATION (US) 2007-12-27 US disclosed
US-20070299039-A1 Substituted benz-azoles and methods of their use as inhibitors of Raf kinase CHIRON CORPORATION (US) 2007-12-27 US disclosed
US-20070299039-A1 Substituted benz-azoles and methods of their use as inhibitors of Raf kinase CHIRON CORPORATION (US) 2007-12-27 US disclosed
EP-1675584-A1 SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF RAF KINASE CHIRON CORPORATION (US) 2006-07-05 EP disclosed
US-7071216-B2 Substituted benz-azoles and methods of their use as inhibitors of Raf kinase CHIRON CORPORATION (US) 2006-07-04 US disclosed
WO-2005032548-A1 SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF RAF KINASE CHIRON CORPORATION (US) 2005-04-14 WO disclosed
EP-1499311-A1 SUBSTITUTED BENZAZOLES AND USE THEREOF AS RAF KINASE INHIBITORS Chiron Corporation (US) 2005-01-26 EP disclosed
US-20040122237-A1 Substituted benzazoles and methods of their use as inhibitors of Raf kinase NOVARTIS AG (CH) 2004-06-24 US disclosed
US-20040087626-A1 Substituted benz-azoles and methods of their use as inhibitors of Raf kinase NOVARTIS AG (CH) 2004-05-06 US disclosed
WO-2003082272-A1 SUBSTITUTED BENZAZOLES AND USE THEREOF AS RAF KINASE INHIBITORS CHIRON CORPORATION (US) 2003-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122237-A1 Substituted benzazoles and methods of their use as inhibitors of Raf kinase BRAF, RAF1, ARAF ALDH1A1 1216/4885L3MBTL1 1929/4885ADRA2C 3421/4885
US-20040087626-A1 Substituted benz-azoles and methods of their use as inhibitors of Raf kinase BRAF, RAF1, ARAF ALDH1A1 1008/4885L3MBTL1 2178/4885ADRA2C 3608/4885
US-20120288501-A1 SUBSTITUTED BENZAZOLES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE BRAF, RAF1, ARAF ALDH1A1 1216/4885L3MBTL1 1929/4885ADRA2C 3421/4885
US-11472794-B2 Fused imidazole derivatives as IL-17 modulators IL17A, IL2, IL23R ALDH1A1 1807/4885L3MBTL1 3057/4885ADRA2C 3065/4885
US-20070299039-A1 Substituted benz-azoles and methods of their use as inhibitors of Raf kinase BRAF, RAF1, ARAF ALDH1A1 1008/4885L3MBTL1 2178/4885ADRA2C 3608/4885
US-20210053952-A1 Fused Imidazole Derivatives as IL-17 Modulators IL17A, IL2, IL23R ALDH1A1 1807/4885L3MBTL1 3057/4885ADRA2C 3065/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.